The Valens Company (TSXV: VLNS) has received its first international shipping order for its white label products.
The order is for an Australian customer, and consists of an initial shipment of over 3,000 units of tinctures. The order is expected to be shipped sometime in the second quarter of 2020, dependent on the timely approval of export and import permits.
Currently, Australia only permits the use of medical cannabis but has increased the approval for medical cannabis products to over 25,000 prescriptions in 2019. This prescription increase is a result of the implementation of an online cannabis application system called Special Access Scheme (SAS). The Australian Therapeutics Goods Administration is presently studying the effects of lower doses of CBD; pending the results of the study, it may be deemed appropriate to allow over-the-counter access of low-dosage CBD.
The Valens Company is a Canadian cannabis extraction and manufacturing company, and is currently trading at $3.72 on the TSX Venture.
Information for this briefing was found via Sedar and Valens GroWorks Corp. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
